MORE►
Dr. George Church
Colossal Biosciences Chief Science Officer Beth Shapiro, Ph.D. [Photo: Business Wire]
Colossal Biosciences Adds Renowned Ancient DNA Expert as Chief Science Officer
by Lance Murray | Mar 19, 2024
Dallas-based Colossal said that in her new role, MacArthur Award winner Beth Shapiro will oversee continued expansion of the company's de-extinction and conservation science teams. The company previously announced plans to "de-extinct" the woolly mammoth, the Tasmanian tiger, and the dodo bird.
by Lance Murray |
Feb 21, 2024
Colossal Biosciences and production partner Teton Ridge Entertainment have signed with James Reed, director of the Oscar-winning Netflix documentary "My Octopus Teacher," and his company Underdog Films, to produce the docuseries.
MORE►
by David Seeley |
Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE►
by David Seeley |
Aug 16, 2022
Colossal is already working to "de-extinct" the woolly mammoth via a mammoth-elephant hybrid project. Now the Tasmanian tiger—which went extinct nearly 100 years ago due to human hunting—is the second species Colossal is seeking to bring back.
"We’re thrilled to be collaborating with Andrew Pask and the University of Melbourne to restore this amazing animal to Earth," said Ben Lamm, Colossal's co-founder and CEO.
MORE►
Colossal leadership team, L to R: Peter Phillips, chief business officer; Andrew Busey, chief product officer; Sarah Grant, chief of staff; Ben Lamm, co-founder/CEO; George Church, PhD, co-founder; Eriona Hysolli, head of biological sciences; Kent Wakeford, COO; and Brian Beard, chief legal officer. [Photo credit: John Davidson Photography]
Mammoth Project: Dallas’ Colossal Raises $60M to Advance Genetic Engineering and ‘De-Extinction’ Technologies
by Quincy Preston and David Seeley | Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
by David Seeley |
Sep 13, 2021
It's not "Jurassic Park," but it's almost as amazing. Hypergiant founder Ben Lamm is launching a new biosciences and genetics startup—Colossal—with $15 million in private funding. The goal: Use genomics to "de-extinct" the woolly mammoth and re-wild it on the Arctic tundra. Lamm's co-founder, Harvard geneticist Dr. George Church, says this "grand vision" could lead to big opportunities in conservation, biodiversity, carbon sequestration, and more.
MORE►
